Barclays PLC Has $3.47 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Barclays PLC grew its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 31.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 100,872 shares of the company's stock after purchasing an additional 24,010 shares during the quarter. Barclays PLC owned approximately 0.18% of Harmony Biosciences worth $3,471,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of HRMY. Vanguard Group Inc. boosted its stake in shares of Harmony Biosciences by 36.4% in the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after purchasing an additional 1,262,362 shares during the last quarter. Norges Bank bought a new stake in shares of Harmony Biosciences in the 4th quarter valued at $16,118,000. Pacer Advisors Inc. boosted its stake in shares of Harmony Biosciences by 18.2% in the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after purchasing an additional 351,582 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Harmony Biosciences by 173.9% in the 4th quarter. Invesco Ltd. now owns 449,180 shares of the company's stock valued at $15,456,000 after purchasing an additional 285,156 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Harmony Biosciences by 28.7% in the 4th quarter. American Century Companies Inc. now owns 1,102,604 shares of the company's stock valued at $37,941,000 after purchasing an additional 246,140 shares during the last quarter. 86.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. UBS Group cut their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $52.44.

Harmony Biosciences Stock Down 0.8 %

Harmony Biosciences stock opened at $29.36 on Tuesday. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 13.91, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80. The firm's fifty day moving average price is $31.84 and its two-hundred day moving average price is $34.23. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.74 by $0.11. The company had revenue of $201.30 million during the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm's revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.45 earnings per share. On average, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.